HIV-1 inhibitor-37 (Compound 83) is a highly powerful HIV-1 inhibitor. It exhibits significant potential for use as an innovative latent HIV-1 reactivating agent [1].
HIV-1 inhibitor-30 (compound 10i) is a potent inhibitor of HIV-1, specifically targeting the RT DNA polymerase enzyme. It exhibits strong antiretroviral activity, with an EC 50 value of 40 nM and an IC 50 value of 80 nM. Furthermore, HIV-1 inhibitor-30 demonstrates significant effectiveness against seven NNRTI-resistant strains of HIV-1 (RT-K103N; RT-Y181C; RT-K103N, Y181C; RT-L100I, K103N; RT-Y188L; RT-K103N, G190A; RT-K103N, V108I), with IC 50 values ranging from 0.04 to 1.42 μM. This compound holds potential for AIDS research [1].
HIV-1 inhibitor-38 (Compound 91) is a powerful agent that inhibits the activity of HIV-1. It exhibits great potential as a novel latency reversing agent, making it a promising candidate for further development [1].
HIV-1 inhibitor-35 (compound 74) is a highly potent inhibitor of the HIV-1 virus, exhibiting EC50 values of 80 nM and 70 nM for LTR and CMV, respectively, in HEK293 cells. Additionally, HIV-1 inhibitor-35 demonstrates inhibitory activity against HepG2 liver cancer cells, with a CC50 value of 40 nM. Moreover, HIV-1 inhibitor-35 shows promise as a potential HIV-1 latency reversing agent [1].